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Although octreotide, a long-acting analogue of somatostatin, is currently used in the treatment of chronic
secretory diarrhoea due to various causes, its role in the management of acute secretory diarrhoea is not well
established. In the present study, therefore, the therapeutic value of octreotide in the management of
cholera, a classical example of acute secretory diarrhoea, was investigated. During an outbreak of cholera,
patients admitted with acute secretory diarrhoea of ::;; 24 h duration and a purging rate >lOO ml/h were
enrolled on the study and randomly assigned to octreotide (N= 17) and control (N= 16) groups. All 33
patients received intravenous fluid replacement and antibiotic treatment (200 mg ofloxacin twice daily for 3
days, by mouth). Each patient in the octreotide group was also given a subcutaneous injection containing
lOO IJ.g octreotide every 8 h for a maximum of six doses. The stool output of each patient was recorded every
hour until there had been none for an hour, which was taken as the endpoint. Mean (s.o.) total stool output
was lower [6·56 (3·7) v. 9·7 (6·5) litres] and the mean (s.o.) duration of diarrhoea after admission was shorter
[32·9 (15·6) v. 47·8 (22·3); P<O·OS] in the octreotide group than in the control group. However, as both
groups generally had similar purging rates, the higher volume of stools from the control group was simply
the result of the longer period of diarrhoea in this group. Octreotide therefore only decreased the duration
of diarrhoea in the cholera patients.

Vibrio cholerae is an important cause of watery
diarrhoea all over the world (Spriggs and
Richard, 1993). The organism remains in the
intestinal lumen, does not invade the mucosal
surface and secretes an enterotoxin which
activates adenylate cyclase, resulting in the
elevated concentration of cyclic AMP in
the intestinal mucosa which is responsible for
the increased intestinal secretion (Field et al.,
1989). There appears to be a differential action
on mucosal cells, there being a direct secretory
effect on the crypt cells (increased chloride
secretion) and some anti-absorption effect on
the villous cells for sodium and chloride (Fine
et al., 1989). In addition, there is some evidence that cholera toxin causes release of
5-hydroxytryptamine; this stimulates the formation of prostaglandin E 2 and so activates
small-bowel flux and secretion (Beugler et al.,
0003-4983/96/050507+07 $12.00/0

1989). The magnitude of the small-bowel flux
overwhelms the absorptive mechanism of the
large bowel and large volumes of stools are
produced.
Cholera is a classical example of secretory
diarrhoea where the balance between absorption and secretion of monovalent ions (Na +,
K +, Cl- , HC0 3 - ) is disturbed. The results
of studies on the efficacy of treatment of
various types of secretory diarrhoea with
somatostatin and its long-acting analogue,
octreotide, have been encouraging. These
drugs have been used to treat chronic diarrhoea following ileostomy (Cooper et al.,
1986), the diarrhoea of tumours producing
vasoactive intestinal polypeptide (Ruskone
et al., 1982; Santangelo et al., 1985), carcinoid (Oberg, 1993) and medullary thyroid
carcmoma (Smid and Dullaart, 1992),
© 1996 Liverpool School of Tropical Medicine
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TABLE 1
Clinical characteristics of the patients in the two study groups
Octreotide

Control

NO. OF PATIENTS

7

Male
Female
All
Mean (s.D.) age (years)
MEAN (S.D.) DURATION OF DIARRHOEA

10
17

7
9
16

43-4 (17·5)

43·2 (17-4)

18·5 (7·0)
32·9 (15·6)

16·1 (6·9)
47-8 (22·3)*

6·56 (3·7)

9·7 (6·5)

(h)

Pre-admission
Post-admission
Mean (s.D.) total stool volume post-admission
(litres)
*P<O·OS.

TABLE 2
Results of laborat01J! tests of the patients at the start of the study
Octreotide group

Control group

MEAN (S.D.) RESULTS OF BLOOD TESTS

Blood urea nitrogen (mM)
Serum creatinine (J.lM)
Random blood sugar (mM)
Serum sodium (mM)
Serum potassium (mM)
Serum chloride (mM)
Serum bicarbonate (mM)

H (1·5)
221·0
10·1
137·5
4·1
107-6
8·8

(141-4)
(3·1)
(5·7)
(1·0)
(H)
(3-8)

2·9
185-6
9·9
136·0
4·1
107-1
8·8

(0·6)
(79·6)
(2·1)
(3-6)
(0·6)
(3-3)
(4·3)

127·5
21·1
113·3
27·5
278·6

(18·9)
(8·0)
(19·2)
(8·1)
(47·5)

130·1
19·8
115·4
22·8
278·9

(16·6)
(8·4)
(16·1)
(10·5)
(19· 5)

MEAN (S.D.) RESULTS OF STOOL TESTS

Sodium (mM)
Potassium (mM)
Chloride (mM)
Bicarbonate (mM)
Stool osmolality (mOsm/kg)

AIDS-related diarrhoea (Manfredi et al.,
1993), short-bowel syndrome (Rosen, 1992),
dumping syndrome (Lamers et al., 1993) and
diabetic diarrhoea (Mourad et al., 1992;
Walker and Kaplan, 1993). Octreotide has
been used in these studies in doses of 50lOO f..lg, given subcutaneously every 8-12 h.
The role of octreotide in the management of
acute secretory diarrhoea has not been extensively studied. The efficacy of this agent in

acute secretory diarrhoea due to Vibrio cholerae
was therefore investigated.

PATIENTS AND METHODS
Patients complaining of acute watery diarrhoea
who were admitted during the summer to the
Medical Unit of The Aga Khan University
Hospital, Karachi, Pakistan, were enrolled on
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TABLE 3
Purging rates (m// h) of the 'on stud)" patimts
Time
post-admission
(h)

Octreotide group

Control group

N

Mean rate and ( s.E.)

N

;\!Jean rate and (s.E.)

17

262·0 (25·2)

16

229·0 (32·0)

1
0-4
5-8
9-12
13-16
17-20
21-24

17
17
16
15
15
13

271·1
247·3
228· 5
234·6
246·8
204-6

(28·8)
(27-6)
(22· 3)
(35·2)
(32·1)
(18·1)

16
16
16
15
15
15

292·5
252·2
235·1
222·2
218·1
201-4

(37-4)
(30·8)
(58·8)
(30-4)
(32·8)
(25·5)

2
0-4
5-8
9-12
13-16
17-20
21-24

13
11
10
6
6
5

134-4
120·3
116·1
162·3
124·8
92·4

(18·9)
(16·5)
(21·6)
(18·4)
(24-9)
(22·7)

14
14
14
11
8
7

201·1
177-2
142·7
164·1
203·1
157·0

(23-6)
(25·3)
(25·6)
(42-4)
(70·8)
(28·6)

3
0-4
5-8
9-12
13-16
17-20
21-24

4
3
1
1
0
0

79· 5 (17-9)
83·3 (33·9)
87
60

6
5
5
5
4
3

170·7
191·0
170·0
125·0
87·2
87·3

(32·8)
(37·7)
(21·6)
(28·6)
(13-5)
(32·1)

4
0-4
5-8
9-12
13-16
17-20
20-24

0
0
0
0
0
0

0
DAY

DAY

DAY

DAY

the study, which was approved by the Ethics
Committee of the hospital. Eligibility criteria
were acute secretory diarrhoea of ~ 24 h duration and a persistent purging rate > 100 ml/h
during the first 8 h post-admission. Children,
pregnant women, patients suffering from other
concurrent illness and patients who had received antimicrobial or antidiarrhoeal agents
before presentation were excluded. Informed
consent was obtained before the patients were
randomly assigned to the treatment group or
the control group. All patients received stan-

206·0
175·0
162·0
150·0
125·0
62·0

dard supportive care, including intravenous
fluid replacement, until there had been no
stool output for an hour, and antibiotic treatment by mouth (200 mg ofloxacin twice daily
for 3 days). Each patient in the treatment
group was also given octreotide by subcutaneous injection for 40 h or until there had
been no stool output for an hour, if this
occurred sooner: 100 J.lg (0· 5 m!) every 8 h.
On presentation, the hydration state of each
patient was assessed from the changes in pulse
and blood pressure that occurred as the patient
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used for samples with unequal standard
deviations and Fisher's exact tests were used
for comparison of discrete variables.
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Fig. 1. The decrease in the numbers of patients 'on
study' (i.e. producing stools every hour) in the
treatment (e) and control ( •) groups.

changed posture. Routine tests comprised
complete blood counts, blood urea nitrogen,
creatinine and electrolytes. Stools were examined and sampled for culture to check whether
Vibrio choleme was present and to determine
electrolyte concentrations and osmolarity.
The secretory nature of the diarrhoea in each
patient was defined by the osmotic gap (i.e. the
difference between stool osmolality measured
directly and that estimated as twice the combined concentrations of N a+ and K +); this was
always :(40 mOsm. Hourly stool outputs were
subsequently measured using rectal catheters
(22F Foley's) connected to urine bags; an
empty bag at the end of a 1-h sampling period
was taken as the end point of the study for each
patient.
Statistical Analysis
All statistical analyses were made using commercial software (Epi-Info). One-way analysis
of variance was used for normally distributed
data. Homogeneity of variance was checked
with Bartlett's test, Mann-Whitney tests were

Overall, 35 patients were initially enrolled in
the study, 18 of whom were given octreotide.
However, two patients, one from each group,
were excluded from the final analysis as Vibrio
cholerae could not be detected in their stool
cultures. The two groups were similar in terms
of patient age and sex and the durations of
diarrhoea before admission (Table 1) and in
terms of their basal concentrations of blood
urea nitrogen, creatinine, random blood sugar,
serum electrolytes and stool electrolytes and
osmolarity (Table 2). The mean (s.o.) duration
of diarrhoea post-admission (Table 1) was
shorter in the octreotide group than in
the control group [32·9 (15·6) v. 47·8 (22· 3 h);
P=0·03]. The one member of the control
group who had diarrhoea for > 3 days (i.e. 4
days) accounted for much of the difference; if
the result for this patient is excluded, the mean
duration of diarrhoea for the remaining controls decreases to 44·6 (18·8) h and the significance of the difference from the result for the
treatment group also decreases (P=0·06).
Mean (s.o.) total stool output was less for the
treatment group [6· 56 (3·7) litres] than for the
controls [9·7 (6·5) litres]. At any particular
time after the first 8 h, the number of 'on
study' patients (i.e. those still producing stools
every hour) was less in the octreotide group
than in the control group, though the difference was never statistically significant (Table
3, Figs 1 and 2). Purging rates (ml/h) for those
'on study' were always the same for the two
groups except at 28 h (P=0·04) (Table 3).
However, pooled purging rates (ml/ day) were
significantly lower in the treatment group on
day 3 than in the controls (P=0·04). No side
effects were noticed by any of the patients
receiving octreotide.
DISCUSSION
The mechanism of secretory diarrhoea in cholera is complex. The cholera toxin activates
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Fig. 2. Changes in purging rates with time in (a) the treatment group and (b) the control group.

adenylate cyclase (AC), a bound enzyme that
is complexed through stimulatory (Gs) and
inhibitory (Gi) G proteins (Gilman, 1984). In
enterocytes, AC is located exclusively in the
basolateral membrane and is stimulated when
the cholera toxin activates Gs; the activated a,
subunit of Gs protein dissociates from the rest
of the apical-membrane-bound molecule and
attaches to the catalytic subunit of AC in the
basolateral membrane, activating the enzyme

(Field et al., 1989). Somatostatin inhibits
enterocyte AC activity by a cholera-toxininsensitive, pertussis-toxin-sensitive Gi protein (Reyl-Desmars et al., 1986). Cholera toxin
also causes release of 5-hydroxytryptamine,
stimulating the formation of prostaglandin E 2
(Beubler et al., 1989). Prostaglandins of the E
series in turn increase water and electrolyte
secretion via the activation of AC (Kimberg
et al., 1971). Somatostatin has also been shown
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to inhibit this activation m an animal model
(Pawlotsky et al., 1993).
Although Fedorak and Alien (1989) failed to
show any alteration m cholera-toxinstimulated secretion in rats given somatostatin
analogue, Yoshioka et al. (1987) had earlier
reported the effectiveness of somatostatin in
the treatment of cholera-induced, secretory
diarrhoea in rats. Yoshioka et al. (1987) found
that the drug had a suppressive effect on the
diarrhoea and inhibited the appearance of
glyco-enzymes in the intestinal lumen and
lymph production induced by the administration of cholera toxin but did not affect the
elevated cAMP concentration. They postulated that the drug exerts its inhibitory effect
beyond cAMP formation. It is possible that
octreotide also fails to alter existing cAMP and
that its effectiveness depends on some other
mechanism. The results of a study by Sjoqvist
(1992) demonstrated the anti-secretory effect
of octreotide in anaesthetized rats and were
consistent with octreotide inhibiting the
nervous secretomotor reflex activated by the
cholera toxin. cAMP induced by cholera toxin
may serve as a physiological mediator for
acetylcholine release from myenteric plexus
neurons. Somatostatin inhibits release of
acetylcholine evoked by various cAMP agonists in a dose-dependent manner (Wiley and
Owyang, 1987). Octreotide has been shown to
increase jejuna! transit time (Dueno et al.,
1987). Somatostatin hyperpolarizes the submucous plexus neurons of guinea-pig by increasing the conductance of a set of inwardly
rectifying potassium channels; this hyperpolarization is unaffected by cholera toxin
(Mihara et al., 1987).
Molla et al. (1984) assessed the ability
of somatostatin to reduce the stool output of cholera patients in a double-blind,

randomized, controlled trial. In this study,
the drug was given for 12 h in a continuous
infusion, was followed by a 12-h observation period and had no apparent effect
on output when compared with control
values from patients given placebo. However, the number of patients studied was
small, the drug was given over a relatively
short period and the follow-up period was
also short, ending while the patients still
had diarrhoea. Although the present results
indicate that octreotide had little effect on
purging rates, the drug did reduce the total
duration of diarrhoea significantly. It may
be that the persistent activity of this longacting analogue of somatostatin overcomes
the secreting factors and eventually shifts
the balance in favour of diarrhoea-inhibiting
mechanisms.
What are the therapeutic implications of this
study? Should we include octreotide in future
regimens of cholera treatment? Diarrhoea was
arrested 14·9 h earlier by adding this expensive
drug to the usual hydration and antibiotic
therapy. Although this improvement may not
make much difference in otherwise healthy
adults, it could be much more significant in the
treatment of the young and the elderly. The
study could not be continued further because
the outbreak of cholera which produced the
influx of patients who were subsequently enrolled ended. A larger randomized trial using
higher dosages may further clarify the role of
octreotide in the management of secretory
diarrhoea due to cholera.
The authors wish to
thank the faculty members of the Department
of Medicine for their contributions to the
study and S. S. Gilani for his secretarial
assistance.
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